October 30, 2025 — Leads & Copy —Arcus Biosciences, Inc. (NYSE: RCUS) has announced the commencement of an underwritten public offering of its common stock.
The biopharmaceutical company, which focuses on developing differentiated molecules and combination therapies for cancer, inflammatory, and autoimmune diseases, will offer all shares. Underwriters may also purchase up to an additional 15% of shares.
Leerink Partners and Goldman Sachs & Co. LLC are joint book-running managers for the offering, which is subject to market conditions.
A shelf registration statement was previously filed with the SEC.
Leerink Partners LLC can be contacted at Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com. Goldman Sachs & Co. LLC can be contacted at Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com.
Source: Arcus Biosciences, Inc.
